Jennifer gave a great presentation at the BP Healthcare Conference today. The emphasis of her presentation was on CLTX Car T, outlining the trial data for GBM, with respect to the 4 different dosage levels. She said that success from the 4 dosage trials would be if the disease control rate was at least 50%. She said that they have had very early positive engagement with the FDA. Jennifer was asked when will CHM get on the radar of big Pharma, and she said probably from starting tomorrow at the SNO Conference, but more realistically once dose levels 3 and 4 are completed for CDH17. She said some announcements will be made early next year with regard to CHMs choice of manufacturer (they are choosing from 4 or 5 companies). She said the emphasis of CHMs presentation tomorrow at the SNO conference would be to show safety and of course the efficacy results. John Hester from PB said at the end of the presentation that given the size of JC smiles, he was expecting good results at SNO.
CHM Price at posting:
31.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)